West Houston Clinical Research Service

Houston, Texas 77055

0 studies enrolling now · 14 studies all time

What they study most

Acute Gastroenteritis, Distal Lateral Subungual Onychomycosis, Influenza, Influenza A, Meningitis, Meningococcal, Meningococcal Vaccines, Norovirus Acute Gastroenteritis, Onychomycosis, Otitis Externa, Respiratory Syncytial Virus, Rosacea, Scabies

Studies at this site

• A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis — Running, not enrolling
• A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus — Completed
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications — Stopped early
• Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza — Stopped early
• Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis — Status unconfirmed
• A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea — Completed
• Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies — Completed
• Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza — Stopped early
• A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies — Completed
• A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age — Completed
• A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa — Stopped early
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years) — Completed
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults — Completed
• A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years — Completed